Enzo BioChem Inc., Manhattan
Biotechnology developer; parent company of Enzo Clinical Labs, of Farmingdale
Second Quarter: Ended Jan. 31
Net revenue: Rose to $23.2 million from $21 million in the year-ago quarter.
Net income: Loss of $10.3 million, compared to a loss of $7.7 million in the same quarter last year.
Company statement: "The fiscal second quarter reflected another quarter of improved operating results, excluding unusually high proxy-related costs and a one-time payment to a former officer to settle litigation and the related legal costs," Barry Weiner, the company president, said in a statement. "Margin improvement reflected a more favorable mix of products at Enzo Life Sciences and a higher percentage of esoteric testing at Enzo Clinical Labs."